Laura Pitlik - 04 Apr 2023 Form 4 Insider Report for Arcadia Biosciences, Inc. (RKDA)

Reporting relationship: Chief Marketing Officer
Issuer ticker: RKDA
Reported as of: 04 Apr 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Apr 2023, 17:30:32 UTC
Prior SEC filing: 18 Aug 2022
Source filing: View source filing
Reporting owner signature: Laura Pitlik, by Attorney-in-fact, Solaeta Chan

Key filing fact

Laura Pitlik filed Form 4 for Arcadia Biosciences, Inc. (RKDA) on 28 Apr 2023.

Key facts

This page summarizes Laura Pitlik's Form 4 filing for Arcadia Biosciences, Inc. (RKDA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Apr 2023, 17:30.

Change

Previous filing in this sequence was filed on 18 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RKDA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +1,500
Change %: +39%
Price: $0.000000
Shares after: 5,300
Date: 04 Apr 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,500
Exercise price: $7.55
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options were granted on 4/4/2023 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.